Jump to content

Recommended Posts

Posted

Screenshot_8.jpg.27517bdf167ae93181e933f7636cda1b.jpg

 

 

A 15-day course of the antiviral nirmatrelvir-ritonavir (Paxlovid) didn't improve symptoms of long COVID, according to a randomized controlled trial that was stopped early for lack of efficacy.

 

The STOP-PASC trial showed no difference in improvement on a combined outcome of fatigue, brain fog, shortness of breath, body aches, and gastrointestinal and cardiovascular symptoms for nirmatrelvir-ritonavir compared with placebo-ritonavir over 10 weeks, Upinder Singh, MD, of Stanford University, and colleagues reported in JAMA Internal Medicine.

...

"I don't think we've shown that Paxlovid doesn't work," Singh told MedPage Today. "We've shown that 15 days of Paxlovid given to this highly vaccinated patient population who has had symptoms for a long time, didn't show any statistically significant difference in the composite [outcome]."

 

(more)

 

MedPage Today

https://www.medpagetoday.com/infectiousdisease/longcovid/110544

 

 

  • Thumbs Up 1

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • Recently Browsing   0 members

    • No registered users viewing this page.



×
×
  • Create New...